Multikinase inhibitor decreasing tumor cell proliferation and reducing tumor angiogenesis.

One 50 mg oral tablet taken daily. Recommended drug taken for 4 weeks on treatment, 2 weeks off treatment.

Gastrointestinal Stromal Tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and advanced renal cell carcinoma.

Myelosuppression

Cardiac: left ventricular dysfunction

Endocrine: hypothyroidism

GI: diarrhea, nausea and vomiting, stomatitis, dyspepsia

Cutaneous: skin discoloration, depigmentation of hair, hand-foot syndrome

Other: fatigue, hypertension, bleeding, edema

Oral medication, taken with or without food

Baseline and periodic follow-up LVEF evaluations are needed for patients with cardiac risk factors; baseline LVEF evaluation should be considered for all patients.

Drug-drug interactions:

Co-administration with ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole may increase sunitinib concentrations. Grapefruit may also increase concentrations.

Co-administration with dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital St. John's Wort may decrease sunitinib concentrations.